Diverse non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors are a class of drugs which selectively inhibit cyclooxygenase-2, provide relief from pain and inflammation. However, they lack anti-thrombotic activity and hence lead to cardiovascular and renal liabilities apart from gastrointestinal irritation. To ameliorate this situation, research can be focus on the products originating from natural products that could offer better relief from inflammation than the currently used commercial drugs. Aspirin blocks the cyclooxygenase enzyme which is involved in the ring closure and the addition of O2 to arachidonic acid, converting it to prostaglandins. The present study is undertaken to analyse the docking efficacy of aspirin with the target protein (2AW1), to assess the best ligand for inhibiting cyclooxygenase and to analyse the docking program by Arguslab. Substituting aspirin ligand by sapelenin F, G, H, I.
https://maviyolculuk.online/
https://mavitur.online/
https://marmaristeknekirala.com.tr
https://tekneturumarmaris.com.tr
https://bodrumteknekirala.com.tr
https://gocekteknekirala.com.tr
https://fethiyeteknekirala.com.tr
Menye cyrille1*, Ngabireng Claude Marie2, Kouam Fogue Simeon3
Journal of In Silico & In Vitro Pharmacology received 203 citations as per google scholar report